孙倍成

文章来源:南京大学医学院发布时间:2018-10-09浏览次数:2722

博士研究生导师简介

姓名

孙倍成

研究方向:

慢性炎症与肝癌肿瘤免疫微环境

联系方式

13776413940


学术兼职:

中华医学会器官移植分会青年委员,中国抗癌协会肝癌专业委员会常委,中华肿瘤学会肝癌学组委员,中国医药生物技术协会组织生物样本库分会常委,江苏省抗癌协会肝癌专业委员会主任委员


个人简介

孙倍成,男,19702月生。现任南京大学医学院附属鼓楼医院(南京鼓楼医院)教授,主任医师,博士生导师,副院长,肝胆胰中心主任。教育部长江学者特聘教授,国家自然科学基金杰出青年基金获得者,国家万人计划领军人才。中华医学会器官移植分会青年委员,中国抗癌协会肝癌专业委员会常委,中华肿瘤学会肝癌学组委员,中国医药生物技术协会组织生物样本库分会常委,江苏省抗癌协会肝癌专业委员会主任委员。20181月作为人才引进就职南京大学医学院附属鼓楼医院,任副院长,肝胆胰中心主任。为江苏省十大医学杰出人才,江苏省委组织部333工程第一层次培养对象, 享受国务院政府特殊津贴。获排名第一的江苏省科学技术一等奖2项,教育部自然科学一等奖1项,同时还获国家科技进步二等奖1项,江苏省科学技术二等奖1项(排名第一)。目前以第一作者或通讯作者发表SCI文章60余篇,总影响因子500余分。主持“精准医学研究”国家重点研发计划1项、国家杰出青年科学基金1项、国家自然科学基金重点课题1项、国家973课题1项,总科研经费3000万元。获国家发明专利6件。“World Journal of Gastroenterology”副主编,“PLOS ONE”杂志学术副主编,“Cancer Management and Research”杂志副主编。“Journal of Hepatology”,“ PLoS Pathogens”,“Oncogene”,“Molecular Medicine”,“Journal of Immunology”等杂志审稿人。

主要从事肝胆外科疾病的外科治疗,包括原发性肝癌、胆管细胞癌、肝门部胆管癌、胆囊癌、各种复杂肝胆管结石、肝血管瘤及肝囊肿等良性肝病的治疗。擅长各种术式的肝切除、肝脏移植、活体肝移植、肝肾联合移植、肝肠联合移植及腹腔器官簇移植。2005年开始主刀实施肝脏肝移植手术,包括活体肝移植,迄今为止已经完成肝切除手术1500例,肝移植300余例,活体肝移植40余例。开展了世界首例成人间“废弃肝脏标本”肝移植,同时首创人造血管替代腔静脉和58段肝静脉的不带肝中静脉右肝肝移植。成功开展江苏省内首例肝、胃、小肠、胰腺、结肠等腹腔器官簇移植。





代表性论文[5年通讯作者和第一作者]

  1. Xia AL, Wang XC, Lu YJ, Lu XJ, Sun B. Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. Oncotarget. 2017 Jul 18;8(52):90521-90531. doi: 10.18632/oncotarget.19361. eCollection 2017 Oct 27. Review. (Corresponding author), (IF: 5.165)

  2. Xu X, Yin Y, Tang J, Xie Y, Han Z, Zhang X, Liu Q, Qin X, Huang X, Sun B. Long non-coding RNA Myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating Myd88 expression through H3K27 modification. Cell Death Dis.2017 Oct 12;8(10):e3124. doi: 10.1038/cddis.2017.519. (Corresponding author), (IF: 5.965)

  3. Lu XJ, Li XH, Yuan ZX, Sun HY, Wang XC, Qi X, Zhang X, Sun B. Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: a multicentre validation in patients with HBV infection. Gut. 2017 Nov 3. pii: gutjnl-2017-315299. doi: 10.1136/gutjnl-2017-315299. [Epub ahead of print] No abstract available. (Corresponding author), (IF: 16.658)

  4. Chen K, Ye H, Lu XJ, Sun B, Liu Q. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. Trends Pharmacol Sci. 2017 Dec;38(12):1041-1051. doi: 10.1016/j.tips.2017.10.002. Epub 2017 Oct 28. Review. (Corresponding author), (IF: 12.797)

  5. Wang XC, Zhang XY, Zhang X, Yuan ZX, Li XH, Wang JC, Sun B, Lu XJ. Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FMVCTE algorithm. J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32338-3. doi: 10.1016/j.jhep.2017.08.038. [Epub ahead of print]  (Corresponding author), (IF: 12.486)

  6. Yan S, Han B, Gao S, Wang X, Wang Z, Wang F, Zhang J, Xu D, Sun B.  Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget. 2017 Jun 16;8(36):60149-60158. doi: 10.18632/oncotarget.18557. (Corresponding author), (IF: 5.168)

  7. Wang X, Lu XJ, Sun B. The pros and cons of dying tumour cells in adaptive immune responses. Nat Rev Immunol. 2017 Sep;17(9):591. doi: 10.1038/nri.2017.87. Epub 2017 Jul 31. (Corresponding author), (IF: 39.932)

  8. Li G, Mu X, Huang X, Qian X, Qin J, Tan Z, Zhang W, Xu X, Tan S, Zhu Z, Li W, Wang X, Wang X, Sun B. Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor: Analysis of a preliminary experience on 15 consecutive cases. Medicine (Baltimore). 2017 Jul;96(29):e7295. doi: 10.1097/MD.0000000000007295. (Corresponding author), (IF: 1.803)

  9. Sun X, Zhangyuan G, Shi L, Wang Y, Sun B, Ding Q. Prognostic and clinicopathological significance of cyclin B expression in patients with breast cancer: A meta-analysis. Medicine (Baltimore). 2017 May;96(19):e6860. doi: 10.1097/MD.0000000000006860. Review. (Corresponding author), (IF: 1.803)

  10. Zhu H, Liu Q, Tang J, Xie Y, Xu X, Huang R, Zhang Y, Jin K, Sun B. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN. Cell Physiol Biochem. 2017;41(6):2289-2306. doi: 10.1159/000475648. Epub 2017 Apr 26. Corresponding author), (IF: 5.104)

  11. Tang J, Xie Y, Xu X, Yin Y, Jiang R, Deng L, Tan Z, Gangarapu V, Tang J, Sun B. Bidirectional transcription of Linc00441 and RB1 via H3K27 modification- dependent way promotes hepatocellular carcinoma. Cell Death Dis. 2017 Mar 16;8(3):e2675. doi: 10.1038/cddis.2017.81. (Corresponding author), (IF: 5.77)

  12. Jiang R, Tang J, Chen Y, Deng L, Ji J, Xie Y, Jia W, Chu W, Sun B. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nature Communications, 2017; Doi: 10.1038/ncomms15129. (Corresponding author), (IF: 11.329)

  13. Deng L, Tang J, Yang H, Cheng C, Lu S, Jiang R, Sun B. MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway. Oncogene. 2017 Jul 13;36(28):3976-3985. doi: 10.1038/onc.2016.491. Epub 2017 Mar 13. Corresponding author) (IF: 8.559)

  14. Tan Z, Liu Q, Jiang R, Lv L, Shoto SS, Maillet I, Quesniaux V, Tang J, Zhang W, Sun B, Ryffel B. Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. Cell Mol Immunol. 2017 Feb 13. (Corresponding author) (IF: 5.897)

  15. Zhang W, Wang X, Huang R, Jin K, Zhangyuan G, Yu W, Yin Y, Wang H, Xu Z, Sun B. Prognostic value of marital status on stage at diagnosis in hepatocellular carcinoma. Sci Rep. 2017 Jan 31;7:41695. (Corresponding author) (IF: 5.228)

  16. Huang R, Wang X, Zhang W, Zhangyuan G, Jin K, Yu W, Xie Y, Xu X, Wang H, Sun B. Down-Regulation of LncRNA DGCR5 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Cell Physiol Biochem. 2016 ; 40(3-4):707-715. (Corresponding author) (IF: 4.652)

  17. Yan S, Wang Z, Wang Z, Duan Q, Wang X, Li J, Sun B. Glutathione S-transferase M1 null genotype related to poor prognosis of colorectal cancer. Tumour Biol. 2016 Aug;37(8):10229-34. (Corresponding author) (IF: 2.926)

  18. Wang X, Zhang W, Tang J, Li J, Xu D, Xie Y, Huang R, Jiang R, Deng L, Zhang X, Chai Y, Qin X, Sun B*. LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway. Cell Death and Disease.2016;7: doi:10.1038/cddis.2016.26 (Corresponding author), (IF:5.77)

  19. Zhuo H, Tang J, Lin Z, Jiang R, Zhang X, Ji J, Wang P, Sun B*.The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma.Mol Carcinog. 2016;55(2):209-19. (Corresponding author), (IF: 4.8)

  20. Font-Burgada J, Sun B*, Karin M. Obesity and Cancer: The Oil that Feeds the Flame. Cell Metab. 2016;23(1):48-62. (Corresponding author), (IF:17.57)

  21. Ji J, Tang J, Deng L, Xie Y, Jiang R, Li G, Sun B*.LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.Oncotarget. 2015;6(40):42813-24. (Corresponding author), (IF:6.627)

  22. Deng L, Yang H, Tang J, Lin Z, Yin A, Gao Y, Wang X, Jiang R, Sun B*. Inhibition of MTA1 by ERα contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis.J Exp Clin Cancer Res. 2015 Oct 26;34:128 (Corresponding author), (IF:4.9)

  23. Wang X, Yan S, Xu D, Li J, Xie Y, Hou J, Jiang R, Zhang C, Sun B*. Aggravated Liver Injury but Attenuated Inflammation in PTPRO-Deficient Mice Following LPS/D-GaIN Induced Fulminant Hepatitis.Cell Physiol Biochem. 2015;37(1):214-24. (Corresponding author), (IF:2.875)

  24. Zhang W, Wang X, Jiang R, Hou J, Mu X, Li G, Sun B*.Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma. Mayo Clinic Proceedings. 2015 Sep;90(9):1187-95. (Corresponding author), (IF:6.262)

  25. Hou J, Deng L, Zhuo H, Lin Z, Chen Y, Jiang R, Chen D, Zhang X, Huang X, Sun B*.PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.J Mol Cell Biol. 2015;7(4):338-50. (Corresponding author), (IF: 6.771)

  26. Wen Y, Han J, Chen J, Dong J, Xia Y, Liu J, Jiang Y, Dai J, Lu J, Jin G, Han J, Wei Q, Shen H, Sun B*, Hu Z. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.Int J Cancer. 2015;137(7):1679-90. (Corresponding author), (IF:5.52)

  27. Wan X, Cheng C, Lin Z, Jiang R, Zhao W, Yan X, Tang J, Yao K, Sun B*, Chen Y. The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells.Oncotarget. 2015;6(11):8822-38. (Corresponding author), (IF:6.627)

  28. Zhang W, Hou J, Wang X, Jiang R, Yin Y, Ji J, Deng L, Huang X, Wang K, Sun B*.PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis.Oncotarget. 2015;6(11):9420-33.(Corresponding author), (IF:6.627)

  29. Zhang W, Jiang R, Hou J, Sun B*.Clinicopathological features and prognostic factors of young patients with surgically treated liver cancer.Medicine (Baltimore). 2015;94(12):e684. (Corresponding author), (IF:5.723)

  30. Tang J, Zhuo H, Zhang X, Jiang R, Ji J, Deng L, Qian X, Zhang F, Sun B*. A novel biomarker, Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death & Disease, 2014; 5:e1549.(Corresponding author), (IF:5.177)

  31.  Jiang R, Chen D, Hou J, Tan Z, Wang Y, Huang X, Wang X, Sun B*. Survival and Inflammation Promotion Effect of PTPRO in Fulminant Hepatitis Is Associated with NF-kappaB Activation. Journal of Immunology. 2014, 193(10):5161-70 (Corresponding author), (IF:5.362)

  32.  Hou J, Xia Y, Jiang R, Chen D, Xu J, Deng L, Huang X, Wang X, Sun B*. PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF-κB. J Hepatol. 2014;60(2):306-312. (corrresponding author) (IF:11.336) .

  33.  Sun B*, Karin M*. The therapeutic value of targeting inflammation in gastrointestinal cancers.Trends Pharmacol Sci. 2014; 35(7):349-57. (Corresponding author), (IF: 11.84)

  34.  Lin Z, Wan X, Jiang R, Deng L, Gao Y, Tang J, Yang Y, Zhao W, Yan X, Yao K, Sun B*, Chen Y*.Epstein-Barr virus-encoded latent membrane protein 2A promotes the epithelial-mesenchymal transition in nasopharyngeal carcinoma via metastatic tumor antigen 1 and mechanistic target of rapamycin signaling induction. J Virol. 2014; 88(20):11872-85. (Co-corrresponding author) (IF:4.648).

  35.  Xu D, Wang X, Yan S, Yin Y, Hou J, Wang X, Sun B. Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma.Tumour Biol. 2014;35(10):10267-73. (corrresponding author) (IF:2.84).

  36.  Yang Y, Hou J, Lin Z, Zhuo H, Chen D, Zhang X, Chen Y, Sun B*. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cell Mol Immunol, 2014; 11: 184-196. (corrresponding author) (IF:4.185) .

  37.  Yan S, Xu D, Sun B*. Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis. Dig Dis Sci, 2013. (IF:2.55)

  38.  Tan, ZM and Sun B*. Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol, 2013. 19(47): 8895-901. (IF:2.433)

  39.  Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, Wang X, Ryffel B, Sun B*. IL-17A plays critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunology, 2013; 191(4):1835-44. (corrresponding author) (IF:5.362)  

  40. Sun B*, Mu X, Wang X. Successful adult-to-adult liver transplantation of an otherwise discarded partial liver allograft with a cavernous hemangioma: new strategy for expanding liver donor pool. Transplantation International, 2013;26(9):e79-80 (corrresponding author) (IF:3.12).

  41.  Mu X, Lin S, Yang J, Chen C, Chen Y, Herzig MC, Washburn K, Halff GA, Walter CA, Sun B*, Sun LZ. TGF-β Signaling Is Often Attenuated during Hepatotumorigenesis, but Is Retained for the Malignancy of Hepatocellular Carcinoma Cells. PLoS One,2013; 8(5):e63436. (co-corrresponding author) (IF:3.534).  

  42.  Jiang R, Zhang C, Xia Y, Qian X, Wang X, Sun B*.Serum interleukin-22 level is a negative prognostic indicator in patients with HBV-related hepatocellular carcinoma.Hepatology, 2014;9(3):1208.(corresponding author) (IF:12.003).

  43.  Chen C, Hou J, Lin Z, Yao M, Jiang R, Wang Y, Gao Y, Shao Q, Deng L, Chen Y, Sun B. A bystander cell-based GM-CSF secreting vaccine synergizes with a low dose of cyclophosphamide and induces therapeutic immune responses against murine hepatocellular carcinoma. Cell Mol Immunol, 2013; 10(4):349-59 (corrresponding author) (IF:4.185).

  44.  Li GQ, Zhang F, Lu H, Lu L, Li XC, Wang XH, Sun B*.Drainage by urostomy bag after blockage of abdominal drain in patients with cirrhosis undergoing hepatectomy. Hepatobiliary Pancreat Dis Int. 2013;12(1):99-102. (corrresponding author) (IF:1.06).

  45.  Qin JJ, Xia YX, Lv L, Wang ZJ, Zhang F, Wang XH, Sun B*.Successful disintegration, dissolution and drainage of intracholedochal hematoma by percutaneous transhepatic intervention.World J Gastroenterol. 2012;18(47):7122-6. (corrresponding author) (IF:2.228).

  46.  Lv L, Wang P, Zhou X, Sun B*. Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol. 2013; 34(3):1451-9. (corrresponding author) (IF:2.84).

  47.  Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, Gao Y, Yao A, Wang X, Yu L, Sun B. IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer. 2013;13:59. (corrresponding author) (IF:3.33).

  48.  Tan Z, Jiang R, Wang X, Wang Y, Lu L, Liu Q, Zheng SG, Sun B*, Ryffel B*. RORγt+IL-17+ neutrophils play a critical role in hepatic ischemia-reperfusion injury. J Mol Cell Biol. 2013;5(2):143-6. (Co-corresponding author) (IF:8.432).

  49. Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, Huang X, Wang X, Sun B*. Estrogen sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology. 2013;57:678-688. (corresponding author) (IF:12.003).

  50.  Sun B*, Karin M*. Obesity, Inflammation and Liver Cancer. Journal of Hepatology. 201256(3): 704-713 (Co-corresponding author) (IF:11.336).

  51.  Jiang R, Tan Z, Deng L, Xia Y, Gao Y, Wang X, Sun B*. IL-22 Promotes Human Hepatocellular Carcinoma By Activation of STAT3. Hepatology. 2011;54(3):900.  (corresponding author) (IF:12.003).

  52.  Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y, Gao Y, Wang X, Sun B*. miR-22 Promotes HBV-Related Hepatocellular Carcinoma Development in Males. Clinical Cancer Research. 2011;17(17):5593-603. (corresponding author) (IF:8.193).

  53.  Chen Y, Yang D, Li S, Gao Y, Jiang R, Deng L, Frankel FR, Sun B*. Development of a Listeria monocytogenes based vaccine against hepatocellular carcinoma. Oncogene. 2012;31(17):2140-52. (corresponding author) (IF: 8.559).

  54.  Yang D, Shao Q, Sun H, Mu X, Gao Y, Jiang R, Hou J, Yao K, Chen Y, Sun B*. Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector.Clin Dev Immunol. 2011;2011:716926. (corresponding author) (IF:3.064).

  55.  Gao Y, Yao A, Zhang W, Lu S, Yu Y, Deng L, Yin A, Xia Y, Sun B*, Wang X. Human mesenchymal stem cells over-expressing pigment epithelium derived factor inhibits hepatocellular carcinoma in nude mice. Oncogene, 2010; 29(19):2784-2794. (Co-corresponding author) (IF:8.559).

  56.  Shi J, Deng L, Gao Y, Zhao L, Wang X, Sun B*. Hydrodynamics based transfect -ion of plasmid encoding RANK-Fc protects against hepatic ischemia/ reperfusion injury in mice. Liver Transplantation, 2010; 16 : 611-620. (corresponding author) (IF: 4.1).  

  57.  Jiang R, Xia Y, Li J, Deng L, Zhao L, Shi J, Wang X, Sun B*. High expression levels of IKKa and IKKb are necessary for the malignant properties of liver cancer. Int J Cancer, 2010; 1261263-1274. (corresponding author) (6.198).

  58.  Zhang W, Qian X, Xia Y, Wang K, Zheng Z, Wang Y, Chao Q, Wang X, Sun B*. Abdominal compartment syndrome associated with capillary leak Syndrome in a case of liver transplantation. Transplantation Proceedings, 2009; 41(9):3927-30. (corresponding author) (IF: 1.055).

  59.  Deng L, Xi L, Yin A, Gao Y, You W, Wang X, Sun B*. Hepatitis B Virus Inhibition in Mice by Lentiviral Vector Mediated Small Interference RNA. BMC Gastroenterol,2009; 9:73. (corresponding author) (IF:2.136).

  60.  Sun B, Karin M. NF-B signaling, liver disease and hepatoprotective agents. Oncogene, 2008;27(48):6228-6244. (IF: 8.559).

  61. Sun B*, Gao Y, Deng L, Li G, Cheng F, Wang X. The Level of Oncogene H-Ras Correlates with Tumorigenicity and Malignancy. Cell Cycle,2008; 7(7):934-939  (Co-corresponding author) (IF:5.243).

  62.  Chen Y, Sun H, Liu G, Wang B, Wang F, Sun B*, Yao K.EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein.Cell Mol Immunol. 2009 Aug;6(4):269-76. (Co-corrresponding author) (IF:4.185).

  63. Sun B*, Zhao C, Li G, Cheng F, Wang X. Late onset of GVHD after liver Transplantation. Transplant Immunology, 2006; 16(3-4).250-253 (Co-corresponding author) (IF; 2.2).

  64. Sun B*, Chen M, Liu S, Hawks CL, Hornsby PJ, Wang XH. Tumorigenic study on hepatocytes coexpressing SV40 with Ras. Molecular Carcinogenesis,200645(3): 213-219. (Co-corresponding author) (IF; 4.77).

  65. Sun B, Chen M, Liu S, Hawks CL,  Hornsby PJ. The minimal set of genetic alterations required for conversion of primary human fibroblasts to cancer cells in the subrenal capsule assay. Neoplasia. 2005 ;7(6):585-93. (IF; 5.47)

  66. Sun B, Chen M, Liu S, Hawks CL, Hornsby PJ. Immortal ALT+ human cells do not require telomerase reverse transcriptase for malignant transformation. Cancer Research., 2005;65(15):6512-5. (IF; 9.284)

  67. Sun B, Huang Q, Hawks CL, Hornsby PJ. Progressive loss of malignant behaviorin telomerase-negative tumorigenic adrenocortical cells in an immunodeficient mouse model: Restoration of tumorigenicity by hTERT. Cancer Research,2004;64(17):6144-6151. (IF; 9.284)

  68.  Yin Y# , Xu X# , Tang J# , Zhang W, Zhangyuan G, Deng L, Lu S, Zhuo H, Sun B. CD97 Promotes Tumor Aggressiveness through the Traditional G Protein-Coupled Receptor-mediated signaling in Hepatocellular Carcinoma. Hepatology. 2018 Apr 27. doi: 10.1002/hep.30068.IF:13.246








承担科研项目[项目负责人]

  1. 基于恶性肿瘤免疫微环境,代谢及耐药相关分子靶标鉴定及干预研究。科技部精准医学重点专项,2016YFC09059001200万元。 项目负责人。2016.7-2021.6

  2. 循环非编码RNA调控肿瘤浸润免疫细胞NF-κB/STAT3网络在肝癌复发与转移中机制及诊断价值研究. 国家自然科学基金重点项目,81430062320万元。项目负责人。2015.1-2018.12

  3. 慢性炎症与肝癌.国家自然科学基金杰出青年基金,81225017280万元。项目负责人。2013.1-2016.12

  4. 肾包膜下细胞移植技术对癌基因致瘤性的重新评价,国家自然科学基金面上项目,3067236727万元。项目负责人。2007.1-2009.12

  5. 慢病毒载体介导的T细胞受体基因治疗EBV相关肿瘤。国家自然科学基金面上项目,3077200332万元。项目负责人。2008.1-2010.12

  6. 性激素及IL-1/IL-1R 通路在原发性肝癌发生中的作用, 国家自然科学基金面上项目,8107202935万元。项目负责人。2011.1-2013.12

  7. 巨噬细胞、T淋巴细胞及其分泌的IL-22等炎症因子对肝脏非可控性炎症恶性转化的调控,国家自然科学基金重大研究计划(培育项目),9102972150万元。项目负责人。2011.1-2013.12

  8. 炎症诱导肿瘤的分子调控网络研究,国家基础研究计划(973), 2012CB910800,课题负责人,240万元。2012.1-2016.12

  9. 教育部新世纪优秀人才基金资助。NCET-09-016050万元。2010.1-2012.12

  10. 江苏省医学重点人才项目。RC2007057100万元。2007.1-2011.12.

  11. 江苏省人民医院创新团队A类,首席科学家,300万元。2011.1-2013.12

  12. 慢病毒载体介导的针对端粒酶的RNA干扰技术联合TK基因治疗肝癌及其它实体肿瘤。国家卫生部重点科研基金项目,wkj-2006-2-120万元。2005.1-2007.12









获奖情况

       1.肿瘤微环境在肝癌发生中的分子机制研究及临床应用。高等学校科学研究优秀成果(自然科学)一等奖。排名第一,2016年度。

2. 肝癌免疫微环境肿瘤靶标发现及临床干预研究。江苏省科学技术一等奖。排名第一,2016年度。

3. 慢性炎症诱导肝癌发生机制及临床干预新策略。江苏省科学技术一等奖。排名第一,2011年度。

4. 细胞移植技术在人体肿瘤致瘤性研究中的应用。江苏省科学技术二等奖。排名第一,2008年度

5. 一种新型细胞移植技术在肿瘤致瘤性研究领域的应用。中华医学科技奖三等奖,排名第一,2009年度。

6. 亲体肝移植治疗Wilson’s病基础及临床研究。国家科技进步奖二等奖,排名第七。2005年度。

7. 小移植肝损伤机制与保护措施的基础研究。中华医学科技奖二等奖,排名第

九。2008年度。

8. 第十一届中国青年科技奖,中国科协及中组部 2010

9. 裘法祖普通外科医学青年奖,裘法祖普通外科医学青年基金,2010

10 第六届吴孟超医学青年基金奖,上海吴孟超医学科技基金会,2012

11. 江苏省有突出贡献的中青年专家 2012

12. 国家自然科学基金委杰出青年基金, 2012

13. 教育部长江学者特聘教授, 2013

14. 人力资源部国家百千万工程国家级人选, 2015

15. 科技部中青年创新领军人才, 2016

16. 科技部精准医学重大专项, 首席科学家, 2016

17. 江苏省十大医学杰出人才, 2016

18. 江苏省委组织部333工程第一层次培养对象, 2016